Purpose: To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. Methods: A synthesis of the literature was performed. Results: In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. Conclusions: The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.
KansaraVSHancockSEMuyaLWCiullaTA.Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions. J Controlled Release. 2022;349:1045-1051. doi:10.1016/j.jconrel.2022.05.061
5.
Del AmoEMRimpeläAKHeikkinenE, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134-185. doi:10.1016/j.preteyeres.2016.12.001
6.
GaballaSAKompellaUBElgarhyO, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11(3):866-893. doi:10.1007/s13346-020-00843-z
7.
ThorneJESugarEAHolbrookJT, et al. Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmol. 2019;126(2):283-295. doi:10.1016/j.ophtha.2018.08.021
8.
PatelSRLinASPEdelhauserHFPrausnitzMR.Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res. 2011;28(1):166-176. doi:10.1007/s11095-010-0271-y
9.
OlsenTWFengXWabnerK, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142(5):777-787.e2. doi:10.1016/j.ajo.2006.05.045
10.
KempenJHAltaweelMMHolbrookJT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmol. 2011;118(10):1916-1926. doi:10.1016/j.ophtha.2011.07.027
11.
JaffeGJPavesioCE.Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmol. 2020;127(10):1395-1404. doi:10.1016/j.ophtha.2020.04.001
del AmoEMUrttiA.Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3):135-143. doi:10.1016/j.drudis.2007.11.002
14.
Naftali Ben HaimLMoisseievE. Drug delivery via the suprachoroidal space for the treatment of retinal diseases. Pharmaceutics. 2021;13(7):967. doi:10.3390/pharmaceutics13070967
15.
RaiUDJPYoungSAThrimawithanaTR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. doi:10.1016/j.drudis.2014.10.010
16.
HancockSEWanCRFisherNEAndinoRVCiullaTA.Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies. Expert Opin Drug Deliv. 2021;18(6):777-788. doi:10.1080/17425247.2021.1867532
17.
CiullaTYehSHariprasadSM.Suprachoroidal drug delivery for clinicians: anatomic principles, clinical data in uveitis, and future directions. Ophthalmic Surg Lasers Imaging Retina. 2022; 53(7):361-366. doi:10.3928/23258160-20220617-01
18.
PatelSRBerezovskyDEMcCareyBEZarnitsynVEdelhauserHFPrausnitzMR.Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53(8):4433-4441. doi:10.1167/iovs.12-9872
19.
EdelhauserHFVerhoevenRSBurkeBStrubleCBPatelSR.Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the suprachoroidal space. Invest Ophthalmol Vis Sci. 2014;55(13):5259.
20.
ShahMWanCKapikBCiullaTA.Post hoc analysis of clinical suprachoroidal injection experience for non-infectious uveitis. Invest Ophthalmol Vis Sci. 2021;62(8):1192.
21.
GoldsteinDADoDNoronhaGKissnerJMSrivastavaSKNguyenQD.Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vis Sci Technol. 2016;5(6):14. doi:10.1167/tvst.5.6.14
22.
YehSKurupSKWangRC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina. 2019;39(10):1880-1888. doi:10.1097/IAE.0000000000002279
23.
YehSKhuranaRNShahM, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis. Ophthalmol. 2020;127(7):948-955. doi:10.1016/j.ophtha.2020.01.006
24.
KhuranaRNMerrillPYehS, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2021;106(8):1139-1144. doi:10.1136/bjophthalmol-2020-317560
25.
HenryCRShahMBarakatMR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol. 2022;106(6):802-806. doi:10.1136/bjophthalmol-2020-318019
26.
SingerMAMerrillPYehSHallCKapikBCiullaTA.Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: a post hoc analysis of PEACHTREE. Clin Experiment Ophthalmol. 2022;50(1): 23-30. doi:10.1111/ceo.14024
27.
MerrillPTHenryCRNguyenQDReddyAKapikBCiullaTA.Suprachoroidal CLS-TA with and without systemic corticosteroid and/or steroid-sparing therapy: a post-hoc analysis of the phase 3 PEACHTREE clinical trial. Ocul Immunol Inflamm. 2021;31(8):1579-1586s. doi:10.1080/09273948.2021.1954199
28.
WykoffCCKhuranaRNLampenSIR, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema. Ophthalmol Retina. 2018;2(8):874-877. doi:10.1016/j.oret.2018.03.008
29.
BarakatMRWykoffCCGonzalezV, et al. Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema. Ophthalmol Retina. 2021;5(1):60-70. doi:10.1016/j.oret.2020.08.007
30.
CampochiaroPAWykoffCCBrownDM, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol Retina. 2018;2(4):320-328. doi:10.1016/j.oret.2017.07.013
31.
Clearside Biomedical, Inc. SAPPHIRE: a randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion. clinicaltrials.gov. 2021. Accessed January 29, 2023. https://clinicaltrials.gov/ct2/show/results/NCT02980874
32.
Clearside Biomedical, Inc. A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion. clinicaltrials.gov. 2021. Accessed January 29, 2023. https://clinicaltrials.gov/ct2/show/study/NCT03203447
33.
KansaraVSMuyaLWCiullaTA.Evaluation of long-lasting potential of suprachoroidal axitinib suspension via ocular and systemic disposition in rabbits. Transl Vis Sci Technol. 2021;10(7):19. doi:10.1167/tvst.10.7.19
34.
Clearside Biomedical, Inc. OASIS: open-label, dose-escalation, phase 1/2a study of the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration. clinicaltrials.gov. 2022. Accessed January 29, 2023. https://clinicaltrials.gov/ct2/show/NCT04626128
KinesRCThompsonCDSpringS, et al. Virus-like particle-drug conjugates induce protective, long-lasting adaptive antitumor immunity in the absence of specifically targeted tumor antigens. Cancer Immunol Res. 2021;9(6):693-706. doi:10.1158/2326-6066.CIR-19-0974
Aura Biosciences. A phase 2 open-label, ascending single and repeat dose escalation trial of belzupacap sarotalocan (AU-011) via suprachoroidal administration in subjects with primary indeterminate lesions and small choroidal melanoma. clinicaltrials.gov.2022. Accessed February 9, 2023. https://clinicaltrials.gov/ct2/show/NCT04417530
41.
Aura Biosciences. A phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma. clinicaltrials.gov. 2022. Accessed February 9, 2023. https://clinicaltrials.gov/ct2/show/study/NCT03052127
ChungSHMollhoffINMishraA, et al. Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes. Hum Gene Ther. 2021;32(13-14):682-693. doi:10.1089/hum.2020.281
44.
National Library of Medicine. RGX-314 gene therapy administered in the suprachoroidal space for participants with neovascular age-related macular degeneration (nAMD). 2023. Accessed February 8, 2023. https://clinicaltrials.gov/ct2/show/NCT04514653
REGENXBIO Inc. A phase 2, randomized, dose-escalation, observation-controlled study to evaluate the efficacy, safety, and tolerability of RGX-314 gene therapy delivered via a single suprachoroidal space (SCS) injections in participants with diabetic retinopathy (DR) without center involved-diabetic macular edema (CI-DME)(ALTITUDE). clinicaltrials.gov. 2022. Accessed February 9, 2023. https://clinicaltrials.gov/ct2/show/NCT04567550
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
